ArticleScientific reports2021

Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study.

Shogo Nakamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.